Multiple people have told me they’re now planning to see “Doctor Moloch,” the play about the AI doctor I brought up last week ...

BridgeBio said this morning that its investigational drug succeeded in a late-stage trial of patients with autosomal dominant ...

Texas also alleges that Johnson & Johnson fraudulently transferred liabilities arising from Tylenol to Kenvue to shield ...

The U.S. has ceded its leadership in critical industries before. It must not do so with China and biotech now, writes the ...

Seth Berkley, former CEO of Gavi, the Vaccine Alliance and co-founder of COVAX, discusses his new book “Fair Doses” and the ...

With chatbots, information-seeking is a conversation, which means it’s relational. That “relationship” might look like the ...

Every clinician knows the drill: ask about substance use, sleep, diet, exercise, and housing. The social history is the part ...

What do Rollerblades and Ozempic have in common? Host Alex Hogan explains in the latest episode of STATus Report.

A psychedelic-like therapy posted encouraging early data, as regulators cleared the drug — not a hallucinogenic — for at-home ...

The company plans to revamp its enterprise of 90,000 clinicians into one more heavily weighted toward employed physicians, ...

Eli Lilly announced a partnership with chipmaker NVIDIA to build what it claims will be the “most powerful supercomputer ...

This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and ...